Journal
CURRENT OPINION IN VIROLOGY
Volume 3, Issue 2, Pages 217-224Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2013.03.001
Keywords
-
Categories
Funding
- Research Foundation - Flanders (FWO)
- KU Leuven geconcerteerde onderzoeksactie [GOA/10/014]
- EU FP7 project SILVER
- EU FP7 project EUVIRNA
- EU FP7 project CCHFever
Ask authors/readers for more resources
Today, small molecule antiviral drugs are available for the treatment of infections with herpesviruses, HIV, HBV and HCV as well as with influenza viruses. Ribavirin, a broad-spectrum (but aspecific) antiviral, has been approved for the treatment of infections with respiratory syncytial virus, HCV and Lassa virus. Yet, for many other viruses that cause life-threatening infections [most of which are considered emerging and/or neglected] there are no drugs available. Ideally, potent and broad-spectrum (i.e., pan-genus or pan-family virus activity) antiviral drugs should be developed whereby one drug could be used for the treatment of a number of such viral infections. We here review recent evolutions in the search for inhibitors of emerging and neglected RNA viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available